Froehner M, Lossnitzer A, Manseck A, Koch R, Noack B, Wirth M P
Department of Urology, University Clinics Carl Gustav Carus, Technical University of Dresden, Dresden, Germany.
Urology. 2000 Sep 1;56(3):373-7. doi: 10.1016/s0090-4295(00)00704-4.
To report our experience treating sarcomas in 20 consecutive patients.
Pretreatment and follow-up data were obtained from 20 adult patients consecutively treated between 1992 and 1998 for primary or locally recurrent genitourinary sarcoma.
Eight patients (40%) were classified as having high-grade and 12 (60%) low-grade disease. Except for 3 patients, the primary treatment was surgery alone. The median follow-up was 52 months. The actuarial disease-specific 5-year survival rate was 84% in all patients and was 100% for patients with Memorial Sloan Kettering Cancer Center (MSKCC) Stages 1-2 and 54% in MSKCC Stages 3-4. The disease-specific survival was significantly better in low-grade tumors (log-rank test, P = 0.0063) and inguinal-scrotal tumors (P = 0.019), tumors 5 cm or less (P = 0.039), and MSKCC Stages 1-2 tumors (P = 0.0035).
The results of this study with a high proportion of low-grade, low-stage, and inguinal-scrotal sarcomas demonstrate the favorable prognosis of these subgroups.
报告我们对连续20例肉瘤患者的治疗经验。
获取了1992年至1998年间连续接受治疗的20例成年原发性或局部复发性泌尿生殖系统肉瘤患者的治疗前和随访数据。
8例患者（40%）被归类为高级别疾病，12例（60%）为低级别疾病。除3例患者外，主要治疗方式为单纯手术。中位随访时间为52个月。所有患者的5年疾病特异性精算生存率为84%，纪念斯隆凯特琳癌症中心（MSKCC）1 - 2期患者为100%，MSKCC 3 - 4期患者为54%。低级别肿瘤（对数秩检验，P = 0.0063）、腹股沟 - 阴囊肿瘤（P = 0.019）、5厘米或更小的肿瘤（P = 0.039）以及MSKCC 1 - 2期肿瘤（P = 0.0035）的疾病特异性生存率显著更高。
本研究中低级别、低分期和腹股沟 - 阴囊肉瘤比例较高，结果表明这些亚组预后良好。
